The Relationship Between Serum Cystatin C and PET-DAT Study in Patients With Parkinson's Disease
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 121
- Locations
- 1
- Primary Endpoint
- Cystatin C assesses the loss of dopaminergic neurons
Study Overview
Brief Summary
To investigate the relationship between serum cystatin C and dopamine receptor(DAT) loss in patients with parkinson's disease(PD)
Detailed Description
Number of people suffered from Parkinson disease (PD) is increasing every year. PET imaging of dopamine transport receptors（DAT） serves as the gold standard for the diagnosis and monitoring of PD development. However, due to high costs and radiation reasons, it is not suitable for long-term follow-up. Serum cystatin C can be easily obtained and cheap as an indicator. In recent years, studies have gradually found that it is related to the progression of H&Y staging of Parkinson's disease. To this extent, we want to further explore whether it can reflect the loss of DAT in the brain. Explore whether it can partially replace the role of DAT imaging for future clinical evaluation.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 20 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients aged between 20 and 80 years and whose laboratory results included the levels of serum Cystatin C within a month from the PET-DAT were recruited.
Exclusion Criteria
- •To make the study cohort more homogeneous, PD patients with either a long-standing duration (≥5 years) or advanced Hoehn and Yahr (H&Y) staging (≥3) were excluded.
Outcomes
Primary Outcomes
Cystatin C assesses the loss of dopaminergic neurons
Time Frame: through study completion, an average of 1 year
Explore whether Cystatin C can respond to the loss of dopaminergic neurons
Secondary Outcomes
No secondary outcomes reported